BioBridgeX
Log inCompare quotes
Modality

Vaccine CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing a vaccine means buying across several platforms (mRNA/LNP, viral vector, protein subunit, conjugate, live-attenuated), since the immune response is the product. Buyers source CRO and CDMO work for antigen design, immunogenicity and potency assays, adjuvant formulation, GMP drug substance and fill-finish, and assay validation. On BioBridgeX, a neutral marketplace, buyers compare qualified suppliers and contract directly with their chosen supplier, free to the buyer.

Vaccine CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Vaccine CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture a Vaccine drug?

A vaccine is unusual among modalities because the thing you are selling is an immune response, not a molecule that acts directly on a target. That one fact reshapes the whole development program. Your readout is not a binding constant or a tumor-growth curve, it is whether the construct raises the right kind of immunity (neutralizing antibodies, a balanced T-cell response, durability over time) and whether it does so without unacceptable reactogenicity. So discovery here is antigen design and selection: choosing the immunogen (a surface protein, a stabilized prefusion conformation, a polysaccharide, an attenuated organism, or an mRNA-encoded antigen), then proving it in immunogenicity and challenge studies in animal models before anything goes near a person.

The other complication is that vaccine is not one platform, it is at least five, and the CRO and CDMO work splits hard along those lines. An mRNA vaccine is an in-vitro-transcription program with LNP encapsulation, so it pulls in RNA drug substance, lipid formulation, and fill-finish. A viral-vector vaccine (adenoviral, for example) is a cell-culture and downstream-purification problem closer to gene therapy. A protein-subunit vaccine is recombinant-protein expression plus, almost always, an adjuvant. A conjugate vaccine chemically links a polysaccharide to a carrier protein. A live-attenuated or inactivated vaccine is classic biologics fermentation or egg or cell-based culture. The capabilities that matter, and the suppliers who have them, are different in each case.

This is exactly where a specialist vaccine CDMO pulls away from a generalist. The wet-lab steps (express a protein, run a bioreactor, fill a vial) look generic on a capability slide, but vaccines carry their own baggage: adjuvant formulation and characterization (aluminum salts, oil-in-water emulsions like squalene-based systems, TLR-agonist adjuvants), a potency assay that actually predicts protection rather than just measuring how much antigen is present, immunogenicity assays validated to read the response (ELISA, neutralization titers, ELISpot, intracellular cytokine staining by flow), and cold-chain or lyophilization to keep a fragile biologic stable. A generalist CDMO can make the drug substance; a vaccine-experienced one knows how to prove it works and how to keep it alive in a vial. Match the supplier to your platform before anything else, because a brilliant mRNA shop is irrelevant to a conjugate program, and vice versa.

How do you choose a CRO or CDMO for Vaccine?

Vaccine is a platform-first decision, more so than most modalities, because the safety, analytical, and manufacturing baggage changes completely between mRNA, viral vector, protein subunit, conjugate, and live-attenuated. Score two or three suppliers against the same written scope (platform, antigen, scale, quality grade, whether adjuvant and fill-finish are included) so you are comparing the same work and not three differently shaped quotes. The checklist below is what actually predicts a usable program.

  • Relevant platform and track record: real, completed work in your specific platform (mRNA/LNP, adenoviral or other viral vector, recombinant protein subunit, polysaccharide conjugate, live-attenuated or inactivated), not a generic vaccine claim. Ask for comparable programs the team has taken from construct to clinical material, and which antigens or vectors they have actually handled.
  • GxP and analytical capability for vaccines: GMP status (21 CFR Part 211, EU GMP) for clinical supply and GLP for the safety package, plus the vaccine-specific analytics that decide the program. That means a validated potency assay tied to the mechanism of protection, immunogenicity readouts (neutralizing-antibody titers, ELISA, ELISpot, intracellular cytokine staining), and identity, purity, and stability methods, qualified or validated rather than improvised per batch.
  • Adjuvant and formulation experience: if your subunit or inactivated program needs an adjuvant, confirm the supplier can formulate and characterize it (aluminum salts, oil-in-water emulsion, liposomal or TLR-agonist systems) and has done so before. For mRNA, confirm LNP encapsulation scope; for lyophilized or cold-chain products, confirm the lyo cycle development and stability program.
  • Capacity and scale: the slot availability and the scale you can grow into, from milligram or small-batch tox material through clinical supply and, if relevant, the very large volumes vaccines often need at commercial. A site built for a few liters is the wrong choice for a population-scale program, and an industrial vaccine plant is over-built for a small therapeutic-vaccine trial. Ask where the critical path sits (often template, seed-bank, raw-material lead times, or assay readiness rather than the core reaction).
  • Regulatory experience: which agencies the supplier has filed and been inspected by (FDA CBER, EMA, WHO prequalification for global-health programs), and whether they understand the vaccine-specific expectations, including the comparability and lot-consistency work regulators look for. A clean inspection history in your target market is worth more than a low per-unit price.
  • IP and confidentiality: who owns process improvements and any platform-derived inventions, how your antigen sequence, vector, or strain is protected, freedom-to-operate on licensed adjuvant or delivery technology (LNP lipids and certain adjuvants are heavily patented), and clean tech-transfer terms if you move the process to another site later.

Frequently asked questions

What CRO and CDMO services does a vaccine program actually need?
It depends on platform, but most programs touch antigen design and selection, immunogenicity testing in animal models (and often a challenge study), a potency assay that predicts protection, and the analytical methods to characterize the construct. On the manufacturing side you need GMP drug substance (RNA, recombinant protein, viral vector, or cultured organism), formulation including any adjuvant or LNP step, and fill-finish, frequently with lyophilization and cold-chain. Because these rarely sit at one supplier, vaccine programs usually pull in several specialists across discovery, preclinical, and CMC.
Why does the vaccine platform change which CDMO I should use?
Because the manufacturing process is almost entirely platform-specific. An mRNA vaccine is in-vitro transcription plus LNP encapsulation. A viral-vector vaccine is cell-culture expansion and downstream purification, closer to gene therapy. A protein-subunit vaccine is recombinant-protein expression plus an adjuvant. A conjugate vaccine is polysaccharide-to-carrier chemistry. A live-attenuated or inactivated vaccine is fermentation or egg/cell culture. A CDMO that is excellent at one of these is often a beginner at another, so match the supplier to your platform before you compare anything else.
What is a potency assay for a vaccine and why is it hard?
A potency assay measures whether a batch can actually do its job, ideally tied to the mechanism of protection rather than just how much antigen is in the vial. That is harder for vaccines than for most drugs because the real endpoint is an immune response, and a simple content measurement does not prove immunogenicity. Depending on the product, potency may use an in-vivo immunization read, a cell-based functional assay, or a validated immunoassay shown to correlate with protection. Regulators expect a potency assay that is meaningful and validated, and developing one is often a rate-limiting, underestimated part of the CMC timeline.
Do I need an adjuvant, and can a CDMO formulate it?
Protein-subunit and inactivated vaccines almost always need an adjuvant to raise a strong enough response; mRNA and viral-vector vaccines generally do not, since the platform itself is immunostimulatory. If you need one, confirm the CDMO can formulate and characterize it, whether that is an aluminum salt, an oil-in-water emulsion (squalene-based systems), a liposomal formulation, or a TLR-agonist adjuvant. Note that several modern adjuvants and many LNP lipids are patented, so check freedom-to-operate and licensing early, not after you have built a process around them.
What immunogenicity assays should a vaccine CRO run?
Expect a panel rather than a single test, because you are characterizing both the antibody and the cellular arm of the response. Common readouts include binding-antibody ELISA, neutralizing-antibody titers (the assay regulators often weigh most heavily), ELISpot and intracellular cytokine staining by flow cytometry for T-cell responses, and sometimes a challenge study in an animal model. The supplier should run these to qualified or validated methods, since this data underpins both your go/no-go decisions and your regulatory case. Ask specifically whether they have a validated neutralization assay for your antigen, because standing one up is slow.
Can BioBridgeX coordinate a multi-platform vaccine program across several suppliers?
Yes. A vaccine program routinely spans more than one supplier: antigen design and immunogenicity at one CRO, drug-substance manufacturing at a platform-specific CDMO, adjuvant or LNP formulation at another, and fill-finish somewhere else. BioBridgeX is a neutral marketplace, so you can source and compare qualified suppliers for each step and contract directly with each chosen supplier in one place. It is free for buyers, suppliers pay a flat 2 percent fee, and coverage spans every indication and modality across the full lifecycle.

Source Vaccine work with one contract

Compare transparent quotes from qualified Vaccine CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes